🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra Therapeutics

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  2. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  3. AG-348

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    2 trials

  4. AIN457 150 mg

    Novartis Pharmaceuticals

    Moderate to Severe Chronic Plaque-Type Psoriasis

    phase 3 small molecule completed

    1 trial

  5. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. ALTUVOCT 2 000 IU powder and solvent for solution for injection, ALTUVOCT 3 000 IU powder and solvent for solution for injection, ALTUVOCT 4 000 IU powder and solvent for solution for injection, ALTUVOCT 250 IU powder and solvent for solution for injection, ALTUVOCT 1 000 IU powder and solvent for solution for injection, ALTUVOCT 500 IU powder and solvent for solution for injection

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 3 small molecule active

    1 trial

  7. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  8. AMG 133, Placebo for AMG 133 (maridebart cafraglutide)

    Amgen

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  9. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  10. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  11. AMG 479

    Takeda

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  12. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  13. AMOXICILLINE/ACIDE CLAVULANIQUE PANPHARMA 2 g/200 mg ADULTES, poudre pour solution injectable

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  14. AMX0035, PL1 Oral powder in sachet, oral use

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  15. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  16. ANHYDROUS DOCETAXEL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CALCIUM LEVOFOLINATE

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  17. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Ningbo Cancer Hospital

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  18. APL-2

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  19. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  20. ARO-APOC3 PFS

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia (HTG)

    phase 3 small molecule active

    1 trial

  21. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Severe hypertriglyceridemia (SHTG)

    phase 3 small molecule active

    1 trial

  22. ARO-APOC3 PFS, Plozasiran Injection Placebo

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertriglyceridemia

    phase 3 small molecule active

    1 trial

  23. ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  24. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources